Live Analyst Rating Changes 23246 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Rami Katkhuda
LIFE

Rami Katkhuda

LifeSci Capital
Wall Street Analyst
★★★★★
#270
on 13Foresight · ranked by our own returns
63%
Success Rate
+16.2%
Average Return
22 of 35 calls profitable · +13.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Rami Katkhuda's ratings turned a profit when each position was held for 1 year — averaging +16.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

121 Buy 3 Hold 0 Sell
Rami's Stock Coverage 14 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VERA
Vera Therapeutics
 Aug 11, 2026 BUY Strong Buy
+131.1% avg upside
19 analysts
$90.00
191.42% Upside
 · ·
JBIO
Jade Biosciences
 Aug 10, 2026 BUY Strong Buy
+155.3% avg upside
16 analysts
$42.00
89.56% Upside
 +6.8% ·
MLTX
MoonLake Immunotherapeutics
 Aug 10, 2026 BUY Strong Buy
+75.6% avg upside
20 analysts
$33.00
100.16% Upside
 -0.2% ·
VRDN
Viridian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+52.1% avg upside
32 analysts
$35.00
48.52% Upside
 +2.4% ·
AMLX
Amylyx Pharmaceuticals Inc
 Aug 06, 2026 BUY Strong Buy
+16.1% avg upside
14 analysts
$24.00
2.40% Upside
 -5.7% ·
YARW
Yarrow Bioscience
 Aug 04, 2026 BUY Strong Buy
-35.4% avg upside
9 analysts
$56.00
33.16% Upside
 -0.7% ·
DNTH
Dianthus Therapeutics
 Aug 04, 2026 BUY Strong Buy
-10.4% avg upside
29 analysts
$125.00
11.94% Upside
 +1.3% ·
IRON
Disc Medicine
 Jul 30, 2026 BUY Strong Buy
+7.2% avg upside
21 analysts
$100.00
23.01% Upside
 -2.2% ·
ELOX
Eloxx Pharmaceuticals
 Jul 22, 2026 BUY Strong Buy
+91.5% avg upside
10 analysts
$40.00
109.50% Upside
 +40.9% ·
MANE
Veradermics, Incorporated
 Jul 18, 2026 BUY Strong Buy
+40.7% avg upside
7 analysts
$170.00
55.34% Upside
 +7.9% ·
ELDN
Eledon Pharmaceuticals
 Jun 27, 2026 BUY Strong Buy
+318.7% avg upside
11 analysts
$8.00
120.18% Upside
 -3.4% ·
MLYS
Mineralys Therapeutics, Inc.
 Jun 01, 2026 BUY Strong Buy
+64.8% avg upside
12 analysts
$54.00
98.43% Upside
 -13.1% ·
MAZE
Maze Therapeutics, Inc.
 May 16, 2026 BUY Strong Buy
+129.3% avg upside
12 analysts
$57.00
108.68% Upside
 +11.3% ·
IVA
Inventiva
 Mar 31, 2026 BUY Strong Buy
+235.3% avg upside
17 analysts
$14.00
194.02% Upside
 -14.4% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Rami Katkhuda — Frequently Asked Questions
How accurate are Rami Katkhuda's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Rami's ratings were profitable over a one-year hold, with an average return of +16.1% per rating, or +13.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Rami ranked on 13Foresight?
Rami Katkhuda is currently ranked #270 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Rami cover?
Rami most recently has ratings on VERA, JBIO, MLTX, VRDN, AMLX, YARW, DNTH, IRON, ELOX, MANE, ELDN, MLYS and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.